Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.BioAlliance Pharma, a specialty pharmaceutical company, has received its main patent on the Lauriad technology in Europe.
Subscribe to our email newsletter
The patent describes and protects a muco-adhesive tablet for various applications in the field of opportunistic infections associated with AIDS and cancer. It has been validated in the main European countries and the opposition period has now expired.
Dominique Costantini, president and CEO of BioAlliance Pharma, said: “The grant of this patent acknowledges the true innovation behind the Lauriad muco-adhesive technology. It reinforces our positioning in the target markets for the Lauriad technology: oropharyngeal candidiasis, labial herpes and chronic pain.”